KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial.

Sean P Collins, Matthew S Shotwell, Jeffrey R Strich, Kevin W Gibbs, Marjolein de Wit, D Clark Files, Michelle Harkins, Kris Hudock, Lisa H Merck, Ari Moskowitz, Krystle D Apodaca, Aaron Barksdale, Basmah Safdar, Ali Javaheri, Jeffrey M Sturek, Harry Schrager, Nicole M Iovine, Brian Tiffany, Ivor Douglas, Joseph Levitt, Adit A Ginde, David N Hager, Nathan Shapiro, Abhijit Duggal, Akram Khan, Michael Lanspa, Peter Chen, Nina Gentile, Estelle Harris, Michelle Gong, Subhashini Sellers, Andrew J Goodwin, Mark A Tidswell, Michael Filbin, Neeraj Desai, Felix Gutiérrez, Vicente Estrada, Joaquin Burgos, Tom Boyles, Jose R Paño-Pardo, Nazreen Hussen, Yves Rosenberg, James Troendle, Gordon R Bernard, Amanda J Bistran-Hall, Kelly Walsh, Jonathan D Casey, Josh DeClercq, Meghan Morrison Joly, Jill Pulley, Todd W Rice, Jonathan S Schildcrout, Li Wang, Matthew W Semler, Wesley H Self, ACTIV-4 Host Tissue Investigators

JAMA Netw Open 7(12) e2448215

PMID39625722
PMCIDPMC11615712
DOI10.1001/jamanetworkopen.2024.48215
发表日期2024-12-03
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: Fostamatinib, a spleen tyrosine kinase inhibitor, has been reported to improve outcomes of COVID-19. OBJECTIVE: To evaluate the efficacy and safety of fostamatinib in adults hospitalized with COVID-19 and hypoxemia. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, phase 3, placebo-controlled, double-blinded randomized clinical trial was conducted at 41 US sites and 21 international sites between November 17, 2021, and September 27, 2023; the last follow-up visit was December 31, 2023. Participants were adults aged 18 years or older hospitalized with acute SARS-CoV-2 infection and hypoxemia. Data were analyzed between January 10 and March 8, 2024. INTERVENTIONS: Fostamatinib, 150 mg orally twice daily for 14 days, or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was oxygen-free days, an ordinal outcome classifying a participant's status at day 28 based on mortality and duration of supplemental oxygen use. An adjusted odds ratio (AOR) greater than 1.0 was considered to indicate superiority of fostamatinib over placebo. A key secondary outcome was 28-day all-cause mortality. Safety outcomes included elevated transaminase values, neutropenia, and hypertension. RESULTS: Of the 400 participants randomized (median age, 67 years [IQR, 58-76 years]; 210 [52.5%] men), 199 received fostamatinib and 201 received placebo. The mean (SD) number of oxygen-free days was 13.4 (12.4) in the fostamatinib group and 14.2 (12.1) in the placebo group (unadjusted mean difference, -1.26 days [95% CI, -3.52 to 1.00 days]; AOR, 0.82 [95% credible interval (CrI), 0.58-1.17]). Mortality at 28 days occurred in 22 of 195 patients (11.3%) in the fostamatinib group and 16 of 197 (8.1%) in the placebo group (AOR, 1.44; 95% CrI, 0.72-2.90). Aspartate aminotransferase elevation occurred more commonly in the fostamatinib group (23 [11.6%]) than in the placebo group (11 [5.5%]; AOR, 2.28; 95% CrI, 1.07-4.84). Other safety outcomes were similar between groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of adults hospitalized with COVID-19 and hypoxemia, fostamatinib did not increase the number of oxygen-free days compared with placebo. These results do not support the hypothesis that fostamatinib improves outcomes among adults hospitalized with hypoxemia during the Omicron era. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04924660.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。